跳至主要内容
临床试验/NCT05422352
NCT05422352已完成不适用

Role of Carnosine in Combination With Vitamin B Complex in Preventing the Progression of Diabetic Neuropathy in Type 2 Diabetes Patients

Beni-Suef University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2021年1月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
1
主要终点
Nerve Growth Factor

研究概览

简要总结

Evaluation of the influence of oral administration of carnosine in combination with vitamin B Complex in preventing the progression of diabetic neuropathy in type 2 diabetes patients.

详细描述

Diabetic peripheral neuropathy (DPN) is considered the most common chronic complication of diabetes mellitus, with an incidence rate of about 50%.

DPN is a group of clinical syndromes that affects single or combined regions in the nervous system and is considered one of the microvascular complications that affect greatly the quality of life of patients due to pain and frequency of hospitalization.

DPN commonly develops silent without symptoms in the early stages and when symptoms start appearing only a few effective therapies are available and that is what causes significant patient suffering and societal burden.

Those mechanisms of pain and treatment remain challenging and are restricted by variable efficacy and side effects of therapies and intensification of glycemic control remain the cornerstone for the prevention or delay of DPN.

Lately, it has been proven that long-term low-grade inflammation has an important role in DPN pathogenesis. Clinical trials in DPN patients with pain and without pain showed that the DPN with pain group had higher inflammation markers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

盲法说明

intervention clinical trial

入排标准

年龄范围
20 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 2 diabetes Patients as per ADA criteria.
  • Patients were showing clinical signs of Diabetic neuropathy verified by a neurologist and confirmed by a score ≥7 on the MNSI questionnaire (Michigan Neuropathy Screening Instrument), with abnormal nerve conduction measurement.
  • Patients on a regular visit to the clinic.

排除标准

  • Patients with neuropathy of non-diabetic origin were excluded.
  • Patients with a BMI of 40 kg/m2 or more and those pregnant or breastfeeding were also excluded

研究组 & 干预措施

Control group

No Intervention

Patients will receive only Vitamin B Complex two tablets per day

intervention Group

Experimental

Patients who will receive carnosine supplementation + Vitamin B complex two tablets per day

干预措施: Carnosine (Dietary Supplement)

结局指标

主要结局

Nerve Growth Factor

时间窗: 3 months

a neurotrophic factor and neuropeptide primarily involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons and investigathypothesized its increase after intervention

Neopterin biomarker

时间窗: 3 months

Neopterin, a marker of inflammation and cellular immune response, is elevated in conditions of T-cell or macrophages activation. Diabetic peripheral neuropathy (DPN) is associated with inflammatory/immune processes therefore Investigators hypothesized that it will decrease after intervention

malondialdehyde biomarker

时间窗: 3 months

it is oxidative stress marker that increases in the lipid peroxidation and inflammation happening during diabetic neuropathy and investigators hypothesized that it will decrease after intervention

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mahitab Hany Ahmed

Principle investigator (Assistant lecturer of clinical pharmacy department )

Beni-Suef University

研究点 (1)

Loading locations...

相似试验